Erratum to: Are results from pharmaceutical-company-sponsored studies available to the public?

Rafael Dal-Ré · Alejandro Pedromingo ·
Manuel García-Losa · Juan Lahuerta · Rafael Ortega

Published online: 12 April 2011
© Springer-Verlag 2011

Erratum to: Eur J Clin Pharmacol (2010) 66:1081–1089
DOI 10.1007/s00228-010-0898-y

The article unfortunately contained a mistake.
The statement for letter b under time to publication should be:

- b. Clinical trials (n=57/94): Median (range) time from trial completion to publication 28.4 (6.0–61.9) months. Phase 1 studies were published 16.7 months (median) after study completion. Remarkably, phase 2 (36.0 months) took about 10 or 6 months longer (median) for publication than phase 3 (26.4 months) or 4 (30.4 months) trials, respectively. Time (median) to publication by therapy area ranged between 18.2 (neurosciences) and 39.1 (vaccines) months. Trials with positive and negative results were published 26.9 (6.0–61.9) and 36.5 (8.2–55.8) months after study completion, respectively.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00228-010-0898-y>.

R. Dal-Ré (✉) · M. García-Losa · J. Lahuerta · R. Ortega
Medical Department, GlaxoSmithKline SA,
Tres Cantos,
Madrid, Spain
e-mail: rafael.dalre@urjc.es

A. Pedromingo
Biometry Department, GlaxoSmithKline SA,
Tres Cantos,
Madrid, Spain

Present Address:

R. Dal-Ré
Department of Preventive Medicine, Public Health and Medical
Immunology and Microbiology, School of Health Sciences,
Rey Juan Carlos University,
Avda Atenas s/n; 28922 Alcorcón,
Madrid, Spain